The active ingredient in Adcetris is brentuximab vedotin. Adcetris contains a monoclonal antibody as well as a chemotherapeutic medication. Adcetris reduces the number of lymphoma cancer cells in the body. It is a type of targeted therapy for lymphoma. This signifies that the medicine specifically targets and eliminates cancer cells. When compared to typical chemotherapy, the goal of targeted therapy is to have a lower impact on healthy cells.
Adcetris is only available in one dosage: 50 milligram (mg). It comes in a single-dose container as a powder. The powder is combined into a liquid solution, which is then administered as an intravenous (IV) infusion by your healthcare professional. (An IV infusion is when the medicine is slowly infused into your vein). Adcetris infusions will most likely be given every 2 or 3 weeks.
➡ Classical Hodgkin lymphoma (cHL)
Adcetris treats cHL that either :
➡ Certain types of T-cell lymphoma
Adcetris is used to treat the following types of T-cell lymphoma, which are also non-Hodgkin lymphoma. :
Most of the adverse effects should disappear within a few days or weeks. However, if they worsen or do not go away, consult your doctor or pharmacist.
This medication will be administered to you by your doctor or nurse. Kindly do not self administer.
Adcetris should be kept in a refrigerator between 2°C and 8°C. To protect the medicine from light keep the vial in the carton.
Is Adcetris a chemotherapy drug?
Adcetris is a cancer treatment that is not a standard chemotherapy. Adcetris combines an antibody with a cancer medication, with the antibody directing the drug to the CD30 target on lymphoma cancer cells.
How and where is Adcetris administered?
Adcetris (brentuximab vedotin) is administered intravenously (IV) into a vein in a doctor's office or outpatient clinic. Depending on your illness, the infusion is normally administered every 2 or 3 weeks. Adcetris is a cancer therapy used to treat several types of lymphoma (blood cancer).
For more information, visit -